C4 Therapeutics Inc. logo

C4 Therapeutics Inc.

CCCC | NASDAQ
Chart Builder DCF Calculator
$3.30
-$0.09 (-2.65%)
At close: Sep 21, 2026, 4:00 PM ET
$3.30
$0 (0.00%)
Pre-market: Sep 22, 2026, 4:00 AM ET

Market Data

Market Cap
$374.82M
Enterprise Value
$168.07M
Beta
2.95
Average Volume
2.97M
Shares Outstanding (Diluted)
130.7M
Shares Change YoY
84.07%
Institutional Ownership
67.02%
Exchange
NASDAQ
ISIN
US12529R1077

Price Performance

Price Change 1M
-16.9%
Price Change 3M
-21.8%
Price Change 6M
22.7%
Price Change YTD
71.0%
Price Change 1Y
26.4%
Price Change 3Y
61.8%
Price Change 5Y
-93.3%
1M CAGR (ann.)
-6.9%
1Y CAGR (ann.)
0.3%
5Y CAGR (ann.)
-41.4%
All-Time CAGR
-28.7%

Valuation

PE Ratio
-3.30
Forward PE
N/A
PEG Ratio
-0.07
Forward PEG
-0.31
PS Ratio
10.41
Forward PS
17.80
PB Ratio
1.48
P/FCF Ratio
-4.27
P/Adj. FCF Ratio
-3.66
P/OCF Ratio
-5.08
EV/Sales
4.80
EV/EBIT
-1.66
EV/EBITDA
-1.71
EV/FCF
-1.97
Earnings Yield
-30.3%
FCF Yield
-23.4%
Adj. FCF Yield
-27.3%

Financial Health

Net Cash
$253.66M
Total Debt
$56.86M
Cash & Short-Term Investments
$253.66M
Total Assets
$359.4M
Current Ratio
5.45
Quick Ratio
5.45
Debt / Equity Ratio
0.23
Debt / EBITDA
-0.58
Debt / FCF
-0.67
OCF / Debt
-1.49
Interest Coverage
0.00
Altman Z-Score
-1.18
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
94.9%
Operating Profit Margin
-319.0%
EBITDA Margin
-280.6%
Net Profit Margin
-289.4%
FCF Margin
-243.7%
Adj. FCF Margin
-284.5%
SBC / Revenue
40.8%
SBC Impact (per share)
-16.8%

Returns

Return on Assets
-28.2%
Return on Equity
-45.5%
Return on Invested Capital
-35.2%
Return on Capital Employed
-35.9%
Return on Tangible Assets
-28.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
29.8%
Revenue CAGR 5Y
0.7%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
30.1%
EPS CAGR 5Y
17.7%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-4.0%
FCF CAGR 5Y
4.8%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
14
EPS Growth Next 3Y
57.7%
Revenue Growth Next 3Y
181.0%
Earnings Date
N/A
EPS Estimate (next Q)
N/A
EPS Growth Est (next Q)
N/A
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$11.33
Price Target Upside
243.3%

Cash Flow

Operating Cash Flow
$-84.87M
Free Cash Flow
$-85.39M
Adj. Free Cash Flow
$-99.7M
FCF Per Share
-$0.65
OCF Per Share
-$0.65
OCF/S Ratio
-242.2%

Income Statement

Revenue
$35.04M
Gross Profit
$33.24M
Operating Income
$-111.77M
EBITDA
$-98.31M
Net Income
$-101.42M
EPS (Diluted)
-$1
Revenue / Employee
$336.91K
Profit / Employee
$-975.15K
Employees
104

© 2026 bestshares.com. All rights reserved.